| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
δPKC
|
|---|---|
| ln Vitro |
Delcasertib hydrochloride (KAI-9803) is made up of an 11-amino acid (arginine-rich) cell-penetrating peptide and a specific delta-protein kinase C (δPKC) inhibitory peptide that is generated from the deltaV1-1 part of deltaPKC. Reversibly bonded disulfide links make up the acidic HIV type 1 transactivator sequence [1].
|
| ln Vivo |
Mice's liver, kidney, lung, heart, and brain exhibit specific inhibition of PKC translocation when administered intraperitoneally with delcasertib hydrochloride (KAI-9803) [1]. When given after the conclusion of ischemia, KAI-9803) was shown to lessen ischemia-reperfusion-induced heart damage in a rat model of acute myocardial infarction [1]. Patients having angioplasty following an acute myocardial infarction have been examined for the prevention of reperfusion injury with delcasertib hydrochloride (KAI-9803) [2].
|
| Animal Protocol |
Animal/Disease Models: Sixweeks old male Crl:CD(SD) rats[1]
Doses: 1 mg/kg (pharmacokinetic/PK Analysis). Route of Administration: Via the femoral vein. Experimental Results: The distribution to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47-57. |
| References |
|
| Molecular Formula |
C120H200CLN45O34S2
|
|---|---|
| Molecular Weight |
2916.74
|
| Related CAS # |
Delcasertib;949100-39-4
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~34.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (17.14 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3428 mL | 1.7142 mL | 3.4285 mL | |
| 5 mM | 0.0686 mL | 0.3428 mL | 0.6857 mL | |
| 10 mM | 0.0343 mL | 0.1714 mL | 0.3428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
